Amyloid precursor protein metabolism is regulated toward alpha-secretase pathway by Ginkgo biloba extracts

Francesca Colciaghi, Barbara Borroni, Martina Zimmermann, Camilla Bellone, Annalisa Longhi, Alessandro Padovani, Flaminio Cattabeni, Yves Christen, Monica Di Luca

Research output: Contribution to journalArticle

87 Citations (Scopus)

Abstract

Clinical trials report that Ginkgo biloba extracts (e.g., EGb761) reduce cognitive symptoms in age-associated memory impairment and dementia, including Alzheimer disease (AD). However, the mechanisms behind their neuroprotective ability remain to be fully established. In this study, the effect of EGb761 on the amyloid precursor protein (APP) metabolism has been investigated by both in vitro and in vivo models. To this aim, alpha-secretase, the enzyme regulating the non-amyloidogenic processing of APP and the release of alphaAPPs, the alpha-secretase metabolite, were studied in superfusates of hippocampal slices after EGb761 incubation, and in hippocampi and cortices of EGb761-treated rats. PKC translocation state was evaluated as well. EGb761 increases alphaAPPs release through a PKC-independent manner. This effect is not accompanied by a modification of either APP forms or alpha-secretase expression. Moreover, EGb761 influence on alphaAPPs release was strictly dependent on treatment dosage. Our findings suggest that the benefit of EGb761 reported by previous clinical studies is underscored by a specific biological mechanism of this compound on APP metabolism, directly affecting the release of the non-amyloidogenic metabolite. Additional research will be needed to clearly define the effective clinical relevance, thus considering EGb761 as a possible supplementary treatment in dementing diseases.

Original languageEnglish
Pages (from-to)454-460
Number of pages7
JournalNeurobiology of Disease
Volume16
Issue number2
DOIs
Publication statusPublished - Jul 2004

Fingerprint

Ginkgo biloba
Amyloid Precursor Protein Secretases
Amyloid beta-Protein Precursor
Neurobehavioral Manifestations
Aptitude
Ginkgo biloba extract 761
Dementia
Hippocampus
Alzheimer Disease
Clinical Trials
Enzymes

Keywords

  • Alpha-secretase activity
  • Alzheimer disease
  • Amyloid precursor protein
  • Ginkgo biloba
  • PKC

ASJC Scopus subject areas

  • Neurology

Cite this

Colciaghi, F., Borroni, B., Zimmermann, M., Bellone, C., Longhi, A., Padovani, A., ... Di Luca, M. (2004). Amyloid precursor protein metabolism is regulated toward alpha-secretase pathway by Ginkgo biloba extracts. Neurobiology of Disease, 16(2), 454-460. https://doi.org/10.1016/j.nbd.2004.03.011

Amyloid precursor protein metabolism is regulated toward alpha-secretase pathway by Ginkgo biloba extracts. / Colciaghi, Francesca; Borroni, Barbara; Zimmermann, Martina; Bellone, Camilla; Longhi, Annalisa; Padovani, Alessandro; Cattabeni, Flaminio; Christen, Yves; Di Luca, Monica.

In: Neurobiology of Disease, Vol. 16, No. 2, 07.2004, p. 454-460.

Research output: Contribution to journalArticle

Colciaghi, F, Borroni, B, Zimmermann, M, Bellone, C, Longhi, A, Padovani, A, Cattabeni, F, Christen, Y & Di Luca, M 2004, 'Amyloid precursor protein metabolism is regulated toward alpha-secretase pathway by Ginkgo biloba extracts', Neurobiology of Disease, vol. 16, no. 2, pp. 454-460. https://doi.org/10.1016/j.nbd.2004.03.011
Colciaghi, Francesca ; Borroni, Barbara ; Zimmermann, Martina ; Bellone, Camilla ; Longhi, Annalisa ; Padovani, Alessandro ; Cattabeni, Flaminio ; Christen, Yves ; Di Luca, Monica. / Amyloid precursor protein metabolism is regulated toward alpha-secretase pathway by Ginkgo biloba extracts. In: Neurobiology of Disease. 2004 ; Vol. 16, No. 2. pp. 454-460.
@article{250e44a3e0c045688c83c39b18eec6fa,
title = "Amyloid precursor protein metabolism is regulated toward alpha-secretase pathway by Ginkgo biloba extracts",
abstract = "Clinical trials report that Ginkgo biloba extracts (e.g., EGb761) reduce cognitive symptoms in age-associated memory impairment and dementia, including Alzheimer disease (AD). However, the mechanisms behind their neuroprotective ability remain to be fully established. In this study, the effect of EGb761 on the amyloid precursor protein (APP) metabolism has been investigated by both in vitro and in vivo models. To this aim, alpha-secretase, the enzyme regulating the non-amyloidogenic processing of APP and the release of alphaAPPs, the alpha-secretase metabolite, were studied in superfusates of hippocampal slices after EGb761 incubation, and in hippocampi and cortices of EGb761-treated rats. PKC translocation state was evaluated as well. EGb761 increases alphaAPPs release through a PKC-independent manner. This effect is not accompanied by a modification of either APP forms or alpha-secretase expression. Moreover, EGb761 influence on alphaAPPs release was strictly dependent on treatment dosage. Our findings suggest that the benefit of EGb761 reported by previous clinical studies is underscored by a specific biological mechanism of this compound on APP metabolism, directly affecting the release of the non-amyloidogenic metabolite. Additional research will be needed to clearly define the effective clinical relevance, thus considering EGb761 as a possible supplementary treatment in dementing diseases.",
keywords = "Alpha-secretase activity, Alzheimer disease, Amyloid precursor protein, Ginkgo biloba, PKC",
author = "Francesca Colciaghi and Barbara Borroni and Martina Zimmermann and Camilla Bellone and Annalisa Longhi and Alessandro Padovani and Flaminio Cattabeni and Yves Christen and {Di Luca}, Monica",
year = "2004",
month = "7",
doi = "10.1016/j.nbd.2004.03.011",
language = "English",
volume = "16",
pages = "454--460",
journal = "Neurobiology of Disease",
issn = "0969-9961",
publisher = "Academic Press Inc.",
number = "2",

}

TY - JOUR

T1 - Amyloid precursor protein metabolism is regulated toward alpha-secretase pathway by Ginkgo biloba extracts

AU - Colciaghi, Francesca

AU - Borroni, Barbara

AU - Zimmermann, Martina

AU - Bellone, Camilla

AU - Longhi, Annalisa

AU - Padovani, Alessandro

AU - Cattabeni, Flaminio

AU - Christen, Yves

AU - Di Luca, Monica

PY - 2004/7

Y1 - 2004/7

N2 - Clinical trials report that Ginkgo biloba extracts (e.g., EGb761) reduce cognitive symptoms in age-associated memory impairment and dementia, including Alzheimer disease (AD). However, the mechanisms behind their neuroprotective ability remain to be fully established. In this study, the effect of EGb761 on the amyloid precursor protein (APP) metabolism has been investigated by both in vitro and in vivo models. To this aim, alpha-secretase, the enzyme regulating the non-amyloidogenic processing of APP and the release of alphaAPPs, the alpha-secretase metabolite, were studied in superfusates of hippocampal slices after EGb761 incubation, and in hippocampi and cortices of EGb761-treated rats. PKC translocation state was evaluated as well. EGb761 increases alphaAPPs release through a PKC-independent manner. This effect is not accompanied by a modification of either APP forms or alpha-secretase expression. Moreover, EGb761 influence on alphaAPPs release was strictly dependent on treatment dosage. Our findings suggest that the benefit of EGb761 reported by previous clinical studies is underscored by a specific biological mechanism of this compound on APP metabolism, directly affecting the release of the non-amyloidogenic metabolite. Additional research will be needed to clearly define the effective clinical relevance, thus considering EGb761 as a possible supplementary treatment in dementing diseases.

AB - Clinical trials report that Ginkgo biloba extracts (e.g., EGb761) reduce cognitive symptoms in age-associated memory impairment and dementia, including Alzheimer disease (AD). However, the mechanisms behind their neuroprotective ability remain to be fully established. In this study, the effect of EGb761 on the amyloid precursor protein (APP) metabolism has been investigated by both in vitro and in vivo models. To this aim, alpha-secretase, the enzyme regulating the non-amyloidogenic processing of APP and the release of alphaAPPs, the alpha-secretase metabolite, were studied in superfusates of hippocampal slices after EGb761 incubation, and in hippocampi and cortices of EGb761-treated rats. PKC translocation state was evaluated as well. EGb761 increases alphaAPPs release through a PKC-independent manner. This effect is not accompanied by a modification of either APP forms or alpha-secretase expression. Moreover, EGb761 influence on alphaAPPs release was strictly dependent on treatment dosage. Our findings suggest that the benefit of EGb761 reported by previous clinical studies is underscored by a specific biological mechanism of this compound on APP metabolism, directly affecting the release of the non-amyloidogenic metabolite. Additional research will be needed to clearly define the effective clinical relevance, thus considering EGb761 as a possible supplementary treatment in dementing diseases.

KW - Alpha-secretase activity

KW - Alzheimer disease

KW - Amyloid precursor protein

KW - Ginkgo biloba

KW - PKC

UR - http://www.scopus.com/inward/record.url?scp=2942590470&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=2942590470&partnerID=8YFLogxK

U2 - 10.1016/j.nbd.2004.03.011

DO - 10.1016/j.nbd.2004.03.011

M3 - Article

C2 - 15193301

AN - SCOPUS:2942590470

VL - 16

SP - 454

EP - 460

JO - Neurobiology of Disease

JF - Neurobiology of Disease

SN - 0969-9961

IS - 2

ER -